Coated implantable medical device
View Patent ↗A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on at least a portion of the coating layer 16, wherein the coating layer 16 provides for the controlled release of the bioactive material from the coating layer. In addition, at least one porous layer 20 can be posited over the bioactive material layer 18, wherein the porous layer includes a polymer and provides for the controlled release of the bioactive material therethrough. Preferably, the structure 12 is a coronary stent. The porous layer 20 includes a polymer applied preferably by vapor or plasma deposition and provides for a controlled release of the bioactive material. It is particularly preferred that the polymer is a polyamide, parylene or a parylene derivative, which is deposited without solvents, heat or catalysts, and merely by condensation of a monomer vapor.
1. A method of making a coated implantable medical device, comprising the steps of:
providing a structure adapted for introduction into a human or veterinary patient, the structure being composed of a base material forming a surface;
positioning a coating layer over the surface;
applying a bioactive material comprising a peptide over the surface of the structure by dipping at least a portion of the coating layer positioned over the surface in a fluid mixture comprising the bioactive material; and
positioning at least one porous layer over the bioactive material and the coating layer, the porous layer controlling the release of the bioactive material from the medical device.
2. The method of claim 1 , wherein porous layer has a thickness of about 5,000 to 250,000 Angstroms.
3. The method of claim 1 , wherein coating layer has a thickness of about 50,000 to 500,000 Angstroms.
4. The method of claim 1 , wherein the total amount of bioactive material applied is about 0.1 to 4 mg/cm 2 of the surface.
5. The method of claim 1 , wherein the bioactive material comprises an antibody.
6. The method of claim 1 , wherein the coating layer consists essentially of phosphatidylcholine.
7. The method of claim 1 , wherein the structure is configured as a vascular stent comprising a biocompatible metal base material;
the coating layer comprises phosphatidylcholine and has a thickness of about 50,000 to 500,000 Angstroms;
the bioactive material comprises an antibody and the total amount of bioactive applied is about 0.1 to 4 mg/cm 2 of the surface; and
the porous layer has a thickness of about 5,000 to 250,000 Angstroms.
8. The method of claim 1 , where the coated implantable medical device contains at least about 0.01 micrograms of the bioactive material per mm 2 of the surface; the total amount of the bioactive material applied to the medical device is about 0.1 to 4 mg/cm 2 of the surface of the coated implantable medical device; and the coated medical device releases at least half of the bioactive material after perfusion for about 10 days in 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS) at about 10 ml/minute.
9. A method of making a coated implantable medical device, comprising the steps of:
providing a vascular stent adapted for introduction into a blood vessel of a human or veterinary patient, the vascular stent being composed of a base material forming a surface comprising a biocompatible metal;
positioning a coating layer over the surface;
applying a bioactive material comprising an antibody over at least a portion of the structure by dipping at least a portion of the coating layer positioned over the surface in a fluid mixture comprising the bioactive material; and
positioning a porous layer over the bioactive material and the coating layer, the porous layer having a thickness effective to provide a controlled release of the bioactive material through the porous layer.
10. The method of claim 9 , further comprising the step of positioning a porous layer comprising phosphatidylcholine over the bioactive material and the coating layer; and the total amount of bioactive material applied to the medical device is about 0.1 to 4 mg/cm 2 of the surface of the coated implantable medical device.
11. The method of claim 10 , wherein
the coating layer comprises phosphatidylcholine and has a thickness of about 50,000 to 500,000 Angstroms;
the bioactive material comprises a GP IIb/IIIa antibody and the total amount of bioactive applied to the medical device is at least about 0.01 micrograms of the antibody per mm 2 of the surface; and
the porous layer comprises phosphatidylcholine, and has a thickness of about 5,000 to 250,000 Angstroms.
12. A method of making a coated implantable medical device, comprising the steps of:
providing a structure adapted for introduction into a human or veterinary patient, the structure being composed of a base material forming a surface;
positioning a coating layer over the surface; and
applying a bioactive material comprising a peptide over at least a portion of the structure by contacting a fluid mixture comprising the bioactive material with at least a portion of the coating layer positioned over the surface;
positioning at least one porous layer comprising phosphatidylcholine over the bioactive material, the porous layer providing for a controlled release of the bioactive material through the porous layer.
13. A method of controlling the release of a bioactive material from an implantable medical device having a structure composed of a base material forming a surface and being adapted for introduction into a human or veterinary patient, the method comprising the steps of:
positioning a coating layer of an adsorbent or absorbent material over the surface;
attaching a bioactive material comprising a peptide to the coating layer by dipping at least a portion of the coating layer positioned over the surface in a fluid mixture comprising the bioactive material; and
positioning at least one porous layer over the bioactive material and the coating layer to form a coated medical device, the porous layer controlling the release of the bioactive material from the coated medical device.
14. The method of claim 13 , where the bioactive material comprises an antibody and the coated medical device releases at least half of the bioactive material after perfusion for about 10 days in 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS) at about 10 ml/minute.
15. The method of claim 14 , where the porous layer comprises phosphatidylcholine.
16. The method of claim 15 , where the coating layer has a thickness of about 50 to 500,000 Angstroms.
17. The method of claim 13 , wherein the bioactive material comprises a protein.
18. The method of claim 13 , wherein the bioactive material comprises an antibody.
19. The method of claim 13 , wherein the bioactive material comprises a GP IIb/IIIa antibody.
20. The method of claim 13 , wherein the coating layer comprises phosphatidylcholine.
21. The method of claim 13 , wherein the base material comprises one or more materials selected from the group consisting of: stainless steel, tantalum, titanium, nitinol, gold, platinum, a biocompatible metal alloy, iridium, silver, tungsten, carbon, carbon fiber, cellulose acetate, cellulose nitrate, silicone, polyethylene teraphthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, polyethylene, polytetrafluoroethylene, polylactic acid, polyglycolic acid, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate extracellular matrix, collagen, and fibrin.
22. The method of claim 13 , wherein the medical device is configured as a vascular stent.
23. The method of claim 13 , wherein the medical device is configured as a vascular stent; the porous layer comprises phosphatidylcholine; and
the coating layer comprises phosphatidylcholine;
the bioactive material comprises a material selected from the group consisting of; a protein and an antibody; and
the base material comprises one or more materials selected from the group consisting of: stainless steel, tantalum, titanium, nitinol, gold, platinum, a biocompatible metal alloy, iridium, silver, tungsten, carbon, carbon fiber, cellulose acetate, cellulose nitrate, silicone, polyethylene teraphthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, polyethylene, polytetrafluoroethylene, polylactic acid, polyglycolic acid, a polyanhydride, polycaprolactone, polyhydroxybutyrate valerate extracellular matrix, collagen, and fibrin.